A Year Of Firsts As Biosimilars Build Momentum In US

Ustekinumab, Denosumab And Eculizumab Rivals Have Hit The Market In 2025

 
• By Dave Wallace
  
More molecules fell to US biosimilar competition for the first time in 2025 (Shutterstock)

More from Growth

More from In Vivo